Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Contraception news

Show

From To
Contraception, HIV and control over black women’s bodies

The apartheid-era practices of injecting women with a controversial contraceptive called Depo-Provera without their consent, is persisting today, according to multiple reports from activists, health workers and women who use public health.

Published
12 February 2018
From
Daily Maverick
Reproductive health of HIV-positive women in Switzerland being neglected, says study

HIV-positive women in Switzerland are mainly relying on male condoms for contraception, investigators report in HIV Medicine. Two-thirds of reproductive age women reported using contraception,

Published
06 February 2018
By
Michael Carter
Withdrawing Depo-Provera contraceptives would result in more lives lost than HIV infections prevented

Even if Depo-Provera and other contraceptive injections raise the risk of HIV infection, withdrawing them from use in African countries would greatly increase maternal mortality, a modelling study

Published
11 January 2018
By
Roger Pebody
Guidelines for the sexual and reproductive health of people living with HIV - consultation open

These BHIVA / BASHH / FSRH guidelines are an update to the 2007 UK guidelines for the management of sexual and reproductive health (SRH) of people living with HIV infection (PLWH). They are open for consultation to Friday 8 December 2017.

Published
13 October 2017
From
BHIVA
South Africa: Parents, principals will no longer decide whether pupils access condoms at schools

School governing bodies and parents will no longer be able to prevent pupils from getting condoms at schools, according to a new basic education department policy released on Wednesday.

Published
14 June 2017
From
Bhekisisa
Taking Birth Control With HIV Treatment or PrEP Is Largely OK

Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).

Published
30 May 2017
From
Poz
HIV, family planning groups grapple with new WHO guidance on popular contraceptive

The World Health Organization's reclassification last month of progestogen-only injectable contraceptives has triggered a critical debate in the family planning community over how to manage the potential link between higher rates of HIV acquisition and one of the most popular birth control methods in many at-risk communities.

Published
04 April 2017
From
Devex
Statement by the ECHO Management Committee on the new WHO guidance on use of hormonal contraceptives by women at high risk of HIV

Injectable progestogens are the most widely used contraceptives in sub-Saharan Africa, including in countries with high HIV prevalence. On 2 March 2017, the World Health Organisation (WHO) released revised guidance on the use of hormonal contraceptives by women at high risk of HIV infection.

Published
06 March 2017
From
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
Hormonal contraceptive eligibility for women at high risk of HIV: Guidance Statement

The World Health Organization (WHO) convened a technical consultation during 1–2 December 2016 to review new evidence on the risk of HIV acquisition with the use of hormonal contraception. The issue was recognized as a critical one, particularly for sub-Saharan Africa, where women have a high lifetime risk of acquiring HIV, hormonal contraceptives constitute a significant component of the contraceptive method mix and unintended pregnancy is a common threat to the well-being and lives of women and girls.

Published
03 March 2017
From
WHO
Vaginal Ring Form of PrEP Does Not Reduce Contraceptive Effectiveness

The antiretroviral (ARV)-containing vaginal ring form of pre-exposure prophylaxis (PrEP) that reduced HIV risk in a major trial does not lower the effectiveness of hormonal birth control. This finding assuages concerns raised by previous research that the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of ARVs has been associated with a lowered effectiveness of some hormonal contraceptives.

Published
16 February 2017
From
Poz
← First12345...12Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.